Th17/Treg imbalance and clinical characteristics in psoriasis patients with metabolic dysfunction-associated steatotic liver disease: a cross-sectional analysis
4 affiliations
- 1Department of Dermatology, Peking University People’s Hospital
- 2Department of Hepatology, Peking University People’s Hospital, Peking University Hepatology Institute
- 3Department of Dermatology, Peking University International Hospital
- 4Health Management Center, Peking University People’s Hospital
Abstract
Background: Psoriasis is a chronic systemic inflammatory disease that imposes a considerable burden of metabolic comorbidities. Metabolic dysfunction-associated steatotic liver disease (MASLD) is particularly common among patients with psoriasis, which may be attributed to shared metabolic and immune-inflammatory pathogenic pathways. However, evidence linking peripheral T-cell profiles to clinical phenotypes remains limited.
Methods: This is a cross-sectional study. A total of 408 participants were enrolled stratified into three groups: 206 patients with plaque psoriasis, 100 subjects undergoing routine health examinations (RHE group), and 102 patients with isolated MASLD. All participants underwent vibration-controlled transient elastography (VCTE) via FibroScan®, with simultaneous acquisition of Liver Stiffness Measurement (LSM) and Controlled Attenuation Parameter (CAP). Comprehensive clinical and laboratory data were collected for further analysis. In a subset of 49 psoriasis participants (32 patients with psoriasis and MASLD and 17 patients with psoriasis alone), peripheral T-cell subpopulations were quantified using flow cytometry.
Results: Psoriasis patients had a higher MASLD prevalence than participants in RHE group (65.5% vs. 46.0%, P = 0.002), with psoriasis independently associated with MASLD (adjusted OR = 2.282, 95% CI: 1.181-4.408). Body mass index (BMI), hyperuricemia, insulin resistance-related indices (triglyceride glucose index [TyG], TyG-BMI), and uric acid-to-high-density lipoprotein cholesterol ratio (UHR) were linked to concomitant MASLD in psoriasis patients. Elevated liver enzymes were associated with severe hepatic steatosis grades. An exploratory model combining BMI, TyG and hyperuricemia exhibited favorable performance for MASLD screening, with an area under the receiver operating characteristic curve (AUC) of 0.84 (95% CI, 0.78-0.89). Compared with patients with psoriasis alone, those with coexisting MASLD showed elevated circulating IL-17+ Th17 cells and an increased Th17/Treg ratio, and this immune imbalance correlated positively with the grade of hepatic steatosis.
Conclusion: Psoriasis is independently associated with MASLD. Psoriasis patients with coexisting MASLD present metabolic abnormalities along with peripheral Th17/Treg immune imbalance. The exploratory model combining BMI, the TyG index and hyperuricemia shows good performance for MASLD screening. These findings highlight the importance of multidisciplinary management for patients with psoriasis.
Related
- Dietary and Nutritional Considerations for Metabolic Dysfunction-Associated Steatotic Liver Disease in Psoriasis and Hidradenitis Suppurativa: A Narrative Review
- Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) : A systematic review and meta-analysis
- Functional and Metabolic Correlates of Age- and Sex-Normalized Handgrip Strength in Children with Metabolic Dysfunction-Associated Steatotic Liver Disease
- Neurological manifestations in metabolic dysfunction syndrome are associated with cumulative metabolic burden beyond hyperglycaemia: a translational study
- Efficacy of plant extracts for metabolic dysfunction-associated steatotic liver disease: a network meta-analysis
BibTeX
@article{dong2026th17treg,
title = {{Th17/Treg imbalance and clinical characteristics in psoriasis patients with metabolic dysfunction-associated steatotic liver disease: a cross-sectional analysis}},
author = {Sai Dong and Zixuan Qiu and Zheng Zhao and Hui Bao and Xiaoyang Liu and Zhanglei Mu and Jianzhong Zhang and Houmin Li and Bo Feng and Lin Cai},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1958145},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1958145/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Th17/Treg imbalance and clinical characteristics in psoriasis patients with metabolic dysfunction-associated steatotic liver disease: a cross-sectional analysis
AU - Sai Dong
AU - Zixuan Qiu
AU - Zheng Zhao
AU - Hui Bao
AU - Xiaoyang Liu
AU - Zhanglei Mu
AU - Jianzhong Zhang
AU - Houmin Li
AU - Bo Feng
AU - Lin Cai
PY - 2026
DA - 2026/10/09
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1958145
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1958145/full
AB - Background: Psoriasis is a chronic systemic inflammatory disease that imposes a considerable burden of metabolic comorbidities. Metabolic dysfunction-associated steatotic liver disease (MASLD) is particularly common among patients with psoriasis, which may be attributed to shared metabolic and immune-inflammatory pathogenic pathways. However, evidence linking peripheral T-cell profiles to clinical phenotypes remains limited. Methods: This is a cross-sectional study. A total of 408 participants were enrolled stratified into three groups: 206 patients with plaque psoriasis, 100 subjects undergoing routine health examinations (RHE group), and 102 patients with isolated MASLD. All participants underwent vibration-controlled transient elastography (VCTE) via FibroScan®, with simultaneous acquisition of Liver Stiffness Measurement (LSM) and Controlled Attenuation Parameter (CAP). Comprehensive clinical and laboratory data were collected for further analysis. In a subset of 49 psoriasis participants (32 patients with psoriasis and MASLD and 17 patients with psoriasis alone), peripheral T-cell subpopulations were quantified using flow cytometry. Results: Psoriasis patients had a higher MASLD prevalence than participants in RHE group (65.5% vs. 46.0%, P = 0.002), with psoriasis independently associated with MASLD (adjusted OR = 2.282, 95% CI: 1.181-4.408). Body mass index (BMI), hyperuricemia, insulin resistance-related indices (triglyceride glucose index [TyG], TyG-BMI), and uric acid-to-high-density lipoprotein cholesterol ratio (UHR) were linked to concomitant MASLD in psoriasis patients. Elevated liver enzymes were associated with severe hepatic steatosis grades. An exploratory model combining BMI, TyG and hyperuricemia exhibited favorable performance for MASLD screening, with an area under the receiver operating characteristic curve (AUC) of 0.84 (95% CI, 0.78-0.89). Compared with patients with psoriasis alone, those with coexisting MASLD showed elevated circulating IL-17+ Th17 cells and an increased Th17/Treg ratio, and this immune imbalance correlated positively with the grade of hepatic steatosis. Conclusion: Psoriasis is independently associated with MASLD. Psoriasis patients with coexisting MASLD present metabolic abnormalities along with peripheral Th17/Treg immune imbalance. The exploratory model combining BMI, the TyG index and hyperuricemia shows good performance for MASLD screening. These findings highlight the importance of multidisciplinary management for patients with psoriasis.
SN - 1664-3224
ER -